|
|
S Zhong, D S Sharp, J S Grove, C Bruce, K Yano, J D Curb, A R Tall
J Clin Invest. 1996;
97(12):2917
doi:10.1172/JCI118751
Abstract |
Full text
| PDF

P
lasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(196)
| Title and authors |
Publication |
Year |
The emerging role of HDL in glucose metabolism
Brian G. Drew, Kerry-Anne Rye, Stephen J. Duffy, Philip Barter, Bronwyn A. Kingwell
|
Nat Rev Endocrinol
|
2012 |
Lipoproteins as biosensors of endothelial oxidative status
Monica Farkas-Epperson, Ngoc-Anh Le
|
Clinical Lipidology
|
2012 |
On- and Off-Target Pharmacology of Torcetrapib : Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors
Douglas G. Johns, Joseph Duffy, Timothy Fisher, Brian K. Hubbard, Michael J. Forrest
|
Drugs
|
2012 |
Metabolic Syndrome
Margrit Schwarz, Jae B. Kim
|
Metabolic Syndrome
|
2011 |
Cholesteryl ester transfer protein: The controversial relation to atherosclerosis and emerging new biological roles
Helena C. F. Oliveira, Eliana C. de Faria
|
IUBMB Life
|
2011 |
Emerging therapeutic strategies to enhance HDL function
Santiago Redondo, José Martínez-González, Concha Urraca, Teresa Tejerina
|
Lipids Health Dis
|
2011 |
Serotonin Levels in Platelet-Poor Plasma and Whole Blood from Healthy Subjects: Relationship with Lipid Markers and Coronary Heart Disease Risk Score
Yuji Hirowatari, Katsuko Hara, Yuko Shimura, Hakuo Takahashi
|
JAT
|
2011 |
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt, Tracy Burgess, Valentin Fuster, Christie M Ballantyne, Evan A Stein, Jean-Claude Tardif
|
The Lancet
|
2011 |
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
Philip Barter, Kerry-Anne Rye
|
Trends in Pharmacological Sciences
|
2011 |
News from the literature: Focus on joint ESC/EAS dyslipidemia guidelines
Jane Stock
|
Atherosclerosis
|
2011 |
|